Roth Lynn, Dogan Soner, Tuna Bilge Guvenc, Aranyi Tamas, Benitez Sonia, Borrell-Pages Maria, Bozaykut Perinur, De Meyer Guido R Y, Duca Laurent, Durmus Nergiz, Fonseca Diogo, Fraenkel Emil, Gillery Philippe, Giudici Alessandro, Jaisson Stéphane, Johansson Madeleine, Julve Josep, Lucas-Herald Angela K, Martinet Wim, Maurice Pascal, McDonnell Barry J, Ozbek Emine Nur, Pucci Giacomo, Pugh Christopher J A, Rochfort Keith D, Roks Anton J M, Rotllan Noemi, Shadiow James, Sohrabi Yahya, Spronck Bart, Szeri Flora, Terentes-Printzios Dimitrios, Tunc Aydin Elif, Tura-Ceide Olga, Ucar Eda, Yetik-Anacak Gunay
Laboratory of Physiopharmacology, University of Antwerp, Antwerp, Belgium.
Department of Medical Biology, School of Medicine, Yeditepe University, Istanbul, Turkiye.
Ageing Res Rev. 2023 Dec;92:102122. doi: 10.1016/j.arr.2023.102122. Epub 2023 Nov 11.
Vascular ageing, characterized by structural and functional changes in blood vessels of which arterial stiffness and endothelial dysfunction are key components, is associated with increased risk of cardiovascular and other age-related diseases. As the global population continues to age, understanding the underlying mechanisms and developing effective therapeutic interventions to mitigate vascular ageing becomes crucial for improving cardiovascular health outcomes. Therefore, this review provides an overview of the current knowledge on pharmacological modulation of vascular ageing, highlighting key strategies and promising therapeutic targets. Several molecular pathways have been identified as central players in vascular ageing, including oxidative stress and inflammation, the renin-angiotensin-aldosterone system, cellular senescence, macroautophagy, extracellular matrix remodelling, calcification, and gasotransmitter-related signalling. Pharmacological and dietary interventions targeting these pathways have shown potential in ameliorating age-related vascular changes. Nevertheless, the development and application of drugs targeting vascular ageing is complicated by various inherent challenges and limitations, such as certain preclinical methodological considerations, interactions with exercise training and sex/gender-related differences, which should be taken into account. Overall, pharmacological modulation of endothelial dysfunction and arterial stiffness as hallmarks of vascular ageing, holds great promise for improving cardiovascular health in the ageing population. Nonetheless, further research is needed to fully elucidate the underlying mechanisms and optimize the efficacy and safety of these interventions for clinical translation.
血管老化的特征是血管的结构和功能发生变化,其中动脉僵硬度和内皮功能障碍是关键组成部分,它与心血管疾病和其他与年龄相关疾病的风险增加有关。随着全球人口持续老龄化,了解其潜在机制并开发有效的治疗干预措施以减轻血管老化,对于改善心血管健康结果至关重要。因此,本综述概述了目前关于血管老化的药理学调节的知识,重点介绍了关键策略和有前景的治疗靶点。已确定几种分子途径是血管老化的核心因素,包括氧化应激和炎症、肾素-血管紧张素-醛固酮系统、细胞衰老、巨自噬、细胞外基质重塑、钙化以及与气体信号分子相关的信号传导。针对这些途径的药理学和饮食干预已显示出改善与年龄相关的血管变化的潜力。然而,针对血管老化的药物的开发和应用因各种内在挑战和限制而变得复杂,例如某些临床前方法学考虑因素、与运动训练的相互作用以及性别/性别相关差异,这些都应予以考虑。总体而言,以内皮功能障碍和动脉僵硬度作为血管老化标志进行药理学调节,对于改善老年人群的心血管健康具有巨大潜力。尽管如此,仍需要进一步研究以充分阐明潜在机制,并优化这些干预措施的疗效和安全性以便进行临床转化。